Media Center

May 26, 2026 Matfors, Sweden / Vienna, Austria — May 26, 2026 NorthX Biologics and enGenes Biotech have partnered to deliver an integrated pathway for recombinant protein expression, process development, and GMP manufacturing in E. coli. The partnership addresses the disconnect between early-stage strain and expression system development and later-stage biologics manufacturing, which can extend development timelines by three to six months. The combined offering helps biopharm

By Alwin Schönberger - profil Nachrichtenmagazin More than five million people are bitten by venomous snakes every year, and at least 100,000 die. Researchers in Vienna have developed a new method to save lives. How the technology works, and why it could also combat other diseases. “There are seven steps until death,” says a proverb in East Africa. According to legend, after being bitten by a black mamba, a person can take exactly seven steps before collapsing lifeless to the

Vienna, Austria: – End-to-end bioprocessing specialist CDMO enGenes Biotech will bring details of its groundbreaking iCAP plasmid DNA continuous production platform to the upcoming annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Dublin. enGenes CEO Dr Jürgen Mairhofer will lead the company’s presence at the conference, which has become recognized as one of the world’s leading events in the field of Cell and Gene Therapy (CGT) Translation, attract

Vienna, Austria: – High-yield end-to-end bioprocessing specialist CDMO enGenes Biotech will be present at the upcoming BioProcess International (BPI) European conference in Vienna in late April 2026. enGenes Business Development Manager Ophelia Gevaert will represent enGenes at the conference to communicate the CDMO’s distinctive offers, technologies and capabilities in high end production of recombinant proteins, plasmid DNA, vaccines, antibodies, and peptides. Proprietary

Vienna, Austria – enGenes Biotech will showcase its industry-leading automated and continuous plasmid DNA (pDNA) production capabilities at the annual BioProcess Summit Europe 2026 in Barcelona. The enGenes team, led by CEO Dr. Juergen Mairhofer, will contribute to the Summit’s Intensified and Continuous Processing stream with a presentation demonstrating the impact of its iCAP platform on next-generation plasmid DNA manufacturing. iCAP: Unlocking continuous bioprocessing O

Introduction Recombinant protein production is essential for pharmaceutical development, diagnostics, and industrial applications. However, achieving high yields of soluble, active proteins – especially for difficult-to-express targets – remains a significant challenge. This article explores advanced solutions for cost-effective protein production, from overcoming expression limitations in standard E. coli strains to implementing extracellular secretion strategies that simpli

Discover the ground-breaking ECOnti project, where enGenes Biotech and partners have developed an integrated continuous manufacturing process that’s transforming biotechnology production. See how multiple industry partners have come together to create a seamless, continuous manufacturing system that enhances efficiency, reduces costs, and advances the future of biotechnology manufacturing. To watch the video, clink on this link: https://www.pharmaceutical-networking.com/econt

Vienna, Austria: – enGenes Biotech GmbH (enGenes) will share details of its progress towards the world’s first platform for truly continuous production of plasmid DNA (pDNA) with the bioscience community at the 44 th International Symposium on the Separation of Proteins, Peptides and Polynucleotides (ISPPP) in Munich. As part of the Continuous and Intensified Processing session, enGenes Senior Bioprocess Scientist Dr. Markus Berg will present “Continuous Downstream Process

Vienna, Austria: – enGenes Biotech GmbH (enGenes) will show its highly advanced bioprocessing solutions in protein expression and vaccine development at Europe’s flagship life sciences partnering conference, BIO-Europe 2025, this year in Vienna. The enGenes team will join other hi-tech biotech companies as part of a combined national presence at the Austrian Pavilion operated by LISAvienna, located at C32 GL in Hall C of the Messe Wien expo center. Enhanced yield expression T

When nucleic acid contamination in protein purification isn’t controlled, you face sticky lysates, slower chromatography, and reduced protein yield. Residual DNA also risks regulatory non-compliance. Learn how using endonucleases effectively can streamline processes, reduce unit economics, and make nuclease treatment a practical solution from early development to large-scale manufacturing. From uncovering how proteins work at the bench to developing therapeutic biologics or s